Intravenous unfractionated heparin in patients. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy1

Blood Platelets

Diseases21

Hemorrhage Venous Thrombosis Pulmonary Embolism Thromboembolism Thrombocytopenia Angina, Unstable Thrombosis Thrombophlebitis Venous Thromboembolism Myocardial Infarction Recurrence Intracranial Hemorrhages Postoperative Hemorrhage Coronary Thrombosis Acute Coronary Syndrome Postoperative Complications Acute Disease Syndrome Angina Pectoris Critical Illness Coronary Disease

Chemicals and Drugs37

Enoxaparin Heparin, Low-Molecular-Weight Heparin Anticoagulants Dalteparin Hirudins Fibrinolytic Agents Antithrombins Nadroparin Factor Xa Heparinoids Antithrombin III Platelet Factor 4 Platelet Glycoprotein GPIIb-IIIa Complex Platelet Aggregation Inhibitors Dermatan Sulfate Polysaccharides Heparin Antagonists Heparin Lyase Thrombin Aspirin Peptide Fragments Pipecolic Acids Recombinant Proteins Heparin Cofactor II Warfarin Immunoglobulin Fab Fragments Prothrombin P-Selectin Vitamin K Tissue Plasminogen Activator Ticlopidine Thromboplastin Glycosaminoglycans von Willebrand Factor Peptides Antibodies, Monoclonal

Analytical, Diagnostic and Therapeutic Techniques and Equipment36

Injections, Subcutaneous Partial Thromboplastin Time Whole Blood Coagulation Time Thrombin Time Treatment Outcome Blood Coagulation Tests Infusions, Intravenous Angioplasty, Balloon, Coronary Drug Therapy, Combination Hirudin Therapy Double-Blind Method Drug Dosage Calculations Stockings, Compression Bleeding Time Platelet Count Injections, Intravenous Drug Administration Schedule Intermittent Pneumatic Compression Devices International Normalized Ratio Prospective Studies Randomized Controlled Trials as Topic Thrombolytic Therapy Incidence Administration, Oral Electrocardiography Single-Blind Method Drug Monitoring Stents Renal Dialysis Risk Assessment Coronary Angiography Risk Factors Myocardial Revascularization Percutaneous Coronary Intervention Follow-Up Studies Retrospective Studies

Phenomena and Processes11

Partial Thromboplastin Time Whole Blood Coagulation Time Thrombin Time Blood Coagulation Dose-Response Relationship, Drug Bleeding Time Platelet Count Platelet Activation Time Factors Decision Trees Platelet Aggregation

Information Science1

Health Care12

Treatment Outcome Double-Blind Method Prospective Studies Randomized Controlled Trials as Topic Incidence Single-Blind Method Risk Assessment Cost-Benefit Analysis Risk Factors Practice Guidelines as Topic Follow-Up Studies Retrospective Studies

Anatomy Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Information Science Health Care

Enoxaparin Heparin, Low-Molecular-Weight Heparin Anticoagulants Hemorrhage Injections, Subcutaneous Dalteparin Hirudins Partial Thromboplastin Time Fibrinolytic Agents Antithrombins Nadroparin Venous Thrombosis Factor Xa Pulmonary Embolism Whole Blood Coagulation Time Heparinoids Antithrombin III Thrombin Time Thromboembolism Blood Coagulation Thrombocytopenia Angina, Unstable Thrombosis Thrombophlebitis Venous Thromboembolism Platelet Factor 4 Platelet Glycoprotein GPIIb-IIIa Complex Treatment Outcome Blood Coagulation Tests Myocardial Infarction Recurrence Platelet Aggregation Inhibitors Dermatan Sulfate Infusions, Intravenous Polysaccharides Heparin Antagonists Heparin Lyase Angioplasty, Balloon, Coronary Thrombin Drug Therapy, Combination Intracranial Hemorrhages Hirudin Therapy Postoperative Hemorrhage Aspirin Peptide Fragments Double-Blind Method Pipecolic Acids Recombinant Proteins Heparin Cofactor II Drug Dosage Calculations Dose-Response Relationship, Drug Stockings, Compression Bleeding Time Platelet Count Warfarin Injections, Intravenous Immunoglobulin Fab Fragments Drug Administration Schedule Coronary Thrombosis Intermittent Pneumatic Compression Devices Acute Coronary Syndrome Postoperative Complications Prothrombin Platelet Activation International Normalized Ratio Acute Disease Time Factors Prospective Studies P-Selectin Randomized Controlled Trials as Topic Thrombolytic Therapy Incidence Decision Trees Vitamin K Tissue Plasminogen Activator Administration, Oral Ticlopidine Electrocardiography Thromboplastin Single-Blind Method Drug Monitoring Stents Renal Dialysis Platelet Aggregation Risk Assessment Syndrome Cost-Benefit Analysis Coronary Angiography Glycosaminoglycans Risk Factors Practice Guidelines as Topic Myocardial Revascularization von Willebrand Factor Angina Pectoris Critical Illness Percutaneous Coronary Intervention Blood Platelets Peptides Coronary Disease

No FAQ available that match "intravenous unfractionated heparin in patients"